Literature DB >> 25983172

IVUS in bifurcation stenting: what have we learned?

Jacek Legutko1, Masahiro Yamawaki, Ricardo A Costa, Marco A Costa.   

Abstract

Coronary angiography is unable to visualise the atherosclerotic involvement of the arterial wall. Bifurcation lesions are particularly difficult to assess by angiography because overlapping mother and daughter vessels often obscure the lesion and carina. On the contrary, IVUS imaging allows for precise, real-time, cross-sectional assessment of all bifurcation lesion segments, enabling measurements of luminal and vessel areas. Moreover, IVUS evaluation of stent expansion, apposition and edge problems is also superior to angiographic assessment. In spite of the lack of adequately powered randomised trials, there is growing evidence from large registries and meta-analyses showing better acute and long-term outcomes of DES implantation guided by IVUS, in comparison to angiography-guided procedures. In this review, we summarise current scientific evidence, the European Society of Cardiology recommendations and the European Bifurcation Club consensus for the use of IVUS in bifurcation stenting.

Entities:  

Mesh:

Year:  2015        PMID: 25983172     DOI: 10.4244/EIJV11SVA12

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  2 in total

1.  Stentless at ostium: a novel approach for treating ostial left anterior descending or left circumflex coronary artery lesions with drug-coated balloons.

Authors:  Wen-Jie Lu; Liang Pan; Zhan-Ying Han; San-Cong Pan; Xi Wang; Ying-Guang Shan; Meng Peng; Xiao-Fei Qin; Guo-Ju Sun; Pei-Sheng Zhang; Jian-Zeng Dong; Chun-Guang Qiu
Journal:  Am J Transl Res       Date:  2022-09-15       Impact factor: 3.940

2.  Prognostic significance of the Medina classification in bifurcation lesion percutaneous coronary intervention with second-generation drug-eluting stents.

Authors:  Leor Perl; Guy Witberg; Gabriel Greenberg; Hana Vaknin-Assa; Ran Kornowski; Abid Assali
Journal:  Heart Vessels       Date:  2019-09-17       Impact factor: 2.037

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.